Involvement of kinase PKC-zeta in the p62/p62P392L-driven activation of NF-κB in human osteoclasts

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 3, 2013, Pages 475-484

  Chamoux, Estelle ^a   McManus, Stephen ^a   Laberge, Gino ^a   Bisson, Martine ^a   Roux, Sophie ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Human osteoclast; P65; Paget's disease of bone; PKC ; SQSTM1 p62

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHALLOIDIN; PROTEASOME; PROTEIN KINASE C; PROTEIN P62; SYNAPTOTAGMIN I; UBIQUITIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; OSTEOCLAST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84872399442     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.12.008     Document Type: Article

References (47)

1. Seitz S., Priemel M., Zustin J., Beil F.T., Semler J., Minne H., Schinke T., Amling M. Paget's disease of bone: histologic analysis of 754 patients. J. Bone Miner. Res. 2009, 24:62-69.
2. Roodman G.D., Windle J.J. Paget disease of bone. J. Clin. Invest. 2005, 115:200-208.
3. Chamoux E., Couture J., Bisson M., Morissette J., Brown J.P., Roux S. The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol. Endocrinol. 2009, 23:1668-1680.
4. Chung P.Y., Van Hul W. Paget's disease of bone: evidence for complex pathogenetic interactions. Semin. Arthritis Rheum. 2012, 41:616-641.
5. Hocking L.J., Lucas G.J., Daroszewska A., Mangion J., Olavesen M., Cundy T., Nicholson G.C., Ward L., Bennett S.T., Wuyts W., Van Hul W., Ralston S.H. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum. Mol. Genet. 2002, 11:2735-2739.
6. Laurin N., Brown J.P., Morissette J., Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet. 2002, 70:1582-1588.
7. Geetha T., Wooten M.W. Structure and functional properties of the ubiquitin binding protein p62. FEBS Lett. 2002, 512:19-24.
8. Hocking L.J., Whitehouse C., Helfrich M.H. Autophagy: a new player in skeletal maintenance?. J. Bone Miner. Res. 2012, 27:1439-1447.
9. Moscat J., Diaz-Meco M.T., Wooten M.W. Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ. 2009, 16:1426-1437.
10. Falchetti A., Di Stefano M., Marini F., Ortolani S., Ulivieri M.F., Bergui S., Masi L., Cepollaro C., Benucci M., Di Munno O., Rossini M., Adami S., Del Puente A., Isaia G., Torricelli F., Brandi M.L. Genetic epidemiology of Paget's disease of bone in Italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone. Calcif. Tissue Int. 2009, 84:20-37.
11. Morissette J., Laurin N., Brown J.P. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J. Bone Miner. Res. 2006, 21(Suppl. 2):P38-P44.
12. Najat D., Garner T., Hagen T., Shaw B., Sheppard P.W., Falchetti A., Marini F., Brandi M.L., Long J.E., Cavey J.R., Searle M.S., Layfield R. Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J. Bone Miner. Res. 2009, 24:632-642.
13. Rea S.L., Walsh J.P., Ward L., Magno A.L., Ward B.K., Shaw B., Layfield R., Kent G.N., Xu J., Ratajczak T. Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-kappaB signaling without loss of ubiquitin binding. J. Bone Miner. Res. 2009, 24:1216-1223.
14. Kurihara N., Hiruma Y., Yamana K., Michou L., Rousseau C., Morissette J., Galson D.L., Teramachi J., Zhou H., Dempster D.W., Windle J.J., Brown J.P., Roodman G.D. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab. 2011, 13:23-34.
15. Daroszewska A., van 't Hof R.J., Rojas J.A., Layfield R., Landao-Basonga E., Rose L., Rose K., Ralston S.H. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Hum. Mol. Genet. 2011, 20:2734-2744.
16. Duran A., Serrano M., Leitges M., Flores J.M., Picard S., Brown J.P., Moscat J., Diaz-Meco M.T. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev. Cell 2004, 6:303-309.
17. Leitges M., Sanz L., Martin P., Duran A., Braun U., Garcia J.F., Camacho F., Diaz-Meco M.T., Rennert P.D., Moscat J. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol. Cell 2001, 8:771-780.
18. Martin P., Duran A., Minguet S., Gaspar M.L., Diaz-Meco M.T., Rennert P., Leitges M., Moscat J. Role of zeta PKC in B-cell signaling and function. EMBO J. 2002, 21:4049-4057.
19. Brady S.C., Allan L.A., Clarke P.R. Regulation of caspase 9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol. Cell. Biol. 2005, 25:10543-10555.
20. Xin M., Gao F., May W.S., Flagg T., Deng X. Protein kinase Czeta abrogates the proapoptotic function of Bax through phosphorylation. J. Biol. Chem. 2007, 282:21268-21277.
21. Roux S., Lambert-Comeau P., Saint-Pierre C., Lepine M., Sawan B., Parent J.L. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem. Biophys. Res. Commun. 2005, 333:42-50.
22. Leach R.J., Singer F.R., Ench Y., Wisdom J.H., Pina D.S., Johnson-Pais T.L. Clinical and cellular phenotypes associated with sequestosome 1 (SQSTM1) mutations. J. Bone Miner. Res. 2006, 21(Suppl. 2):P45-P50.
23. Cloutier A., Ear T., Blais-Charron E., Dubois C.M., McDonald P.P. Differential involvement of NF-kappaB and MAP kinase pathways in the generation of inflammatory cytokines by human neutrophils. J. Leukoc. Biol. 2007, 81:567-577.
24. Seibenhener M.L., Babu J.R., Geetha T., Wong H.C., Krishna N.R., Wooten M.W. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol. Cell. Biol. 2004, 24:8055-8068.
25. Duran A., Linares J.F., Galvez A.S., Wikenheiser K., Flores J.M., Diaz-Meco M.T., Moscat J. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008, 13:343-354.
26. Hirai T., Chida K. Protein kinase Czeta (PKCzeta): activation mechanisms and cellular functions. J. Biochem. (Tokyo) 2003, 133:1-7.
27. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
28. Moscat J., Diaz-Meco M.T., Albert A., Campuzano S. Cell signaling and function organized by PB1 domain interactions. Mol. Cell 2006, 23:631-640.
29. Cavey J.R., Ralston S.H., Sheppard P.W., Ciani B., Gallagher T.R., Long J.E., Searle M.S., Layfield R. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif. Tissue Int. 2006, 78:271-277.
30. Heinen C., Garner T.P., Long J., Bottcher C., Ralston S.H., Cavey J.R., Searle M.S., Layfield R., Dantuma N.P. Mutant p62/SQSTM1 UBA domains linked to Paget's disease of bone differ in their abilities to function as stabilization signals. FEBS Lett. 2010, 584:1585-1590.
31. Long J., Garner T.P., Pandya M.J., Craven C.J., Chen P., Shaw B., Williamson M.P., Layfield R., Searle M.S. Dimerisation of the UBA domain of p62 inhibits ubiquitin binding and regulates NF-kappaB signalling. J. Mol. Biol. 2010, 396:178-194.
32. Wooten M.W., Geetha T., Seibenhener M.L., Babu J.R., Diaz-Meco M.T., Moscat J. The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J. Biol. Chem. 2005, 280:35625-35629.
33. Mitchell B.S. The proteasome-an emerging therapeutic target in cancer. N. Engl. J. Med. 2003, 348:2597-2598.
34. Ang E., Pavlos N.J., Rea S.L., Qi M., Chai T., Walsh J.P., Ratajczak T., Zheng M.H., Xu J. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J. Cell. Physiol. 2009, 220:450-459.
35. Lallena M.J., Diaz-Meco M.T., Bren G., Paya C.V., Moscat J. Activation of IkappaB kinase beta by protein kinase C isoforms. Mol. Cell. Biol. 1999, 19:2180-2188.
36. Otero J.E., Dai S., Alhawagri M.A., Darwech I., Abu-Amer Y. IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J. Bone Miner. Res. 2010, 25:1282-1294.
37. Neumann M., Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J. 2007, 21:2642-2654.
38. Viatour P., Merville M.P., Bours V., Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 2005, 30:43-52.
39. Jiang X., Takahashi N., Matsui N., Tetsuka T., Okamoto T. The NF-kappa B activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536. J. Biol. Chem. 2003, 278:919-926.
40. Sakurai H., Chiba H., Miyoshi H., Sugita T., Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 1999, 274:30353-30356.
41. Wang D., Westerheide S.D., Hanson J.L., Baldwin A.S. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J. Biol. Chem. 2000, 275:32592-32597.
42. Duran A., Diaz-Meco M.T., Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J. 2003, 22:3910-3918.
43. Bohuslav J., Chen L.F., Kwon H., Mu Y., Greene W.C. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 2004, 279:26115-26125.
44. Huang H., Ryu J., Ha J., Chang E.J., Kim H.J., Kim H.M., Kitamura T., Lee Z.H., Kim H.H. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL. Cell Death Differ. 2006, 13:1879-1891.
45. Seibenhener M.L., Geetha T., Wooten M.W. Sequestosome 1/p62-more than just a scaffold. FEBS Lett. 2007, 581:175-179.
46. Rea S.L., Walsh J.P., Ward L., Yip K., Ward B.K., Kent G.N., Steer J.H., Xu J., Ratajczak T. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J. Bone Miner. Res. 2006, 21:1136-1145.
47. Sundaram K., Shanmugarajan S., Rao D.S., Reddy S.V. Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone. Endocrinology 2011, 152:4180-4189.